Is Windtree Therapeutics, Inc. overvalued or undervalued?

As of 16 August 2019, the valuation grade for Windtree Therapeutics, Inc. moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued given its financial ratios, including a Price to Book Value of 0.18 and an EV to Capital Employed of 0.19, both of which suggest poor asset utilization and financial performance. Additionally, the company has a negative ROCE of -217.14% and ROE of -224.59%, highlighting severe inefficiencies in generating returns for shareholders.
In comparison to its peers, Windtree Therapeutics, Inc. has an EV to EBITDA of -0.09, which is less favorable than Aileron Therapeutics, Inc. at -1.6430 and Soligenix, Inc. at -0.5878. This further reinforces the notion that Windtree is not only struggling in its operational metrics but also underperforming relative to similar companies in the sector. Overall, the combination of poor financial ratios and a lack of positive returns suggests that Windtree Therapeutics, Inc. is overvalued in the current market context.